| Company Name: |
Labnetwork lnc. |
| Tel: |
+86-27-50766799 +8618062016861 |
| Email: |
contact@labnetwork.com |
| Products Intro: |
Product Name:3-((4S,7S,10S)-7-(4-aminobutyl)-4-((carboxymethyl)carbamoyl)-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2H-benzo[b][1,5,8,11]oxatriazacyclotetradecin-10-yl)propanoic acid
CAS:263251-78-1
Purity:95% Package:100g; 1kg Remarks:LN03282945
|
|
|
|
|
| Company Name: |
Shanghai Biopharmaleader Co., Ltd.
|
| Tel: |
+86 18721201413 |
| Email: |
sales@biopharmaleader.com |
| Products Intro: |
Product Name:Tavilermide
CAS:263251-78-1
Purity:98%HPLC Package:10g,100g
|
Tavilermide manufacturers
- Tavilermide
-
- $447.00 / 5mg
-
2024-10-28
- CAS:263251-78-1
- Min. Order:
- Purity: 98.98%
- Supply Ability: 10g
|
| | Tavilermide Basic information |
| Product Name: | Tavilermide | | Synonyms: | Tavilermide;3-((4S,7S,10S)-7-(4-aminobutyl)-4-((carboxymethyl)carbamoyl)-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2H-benzo[b][1,5,8,11]oxatriazacyclotetradecin-10-yl)propanoic acid(WXG02263);Glycine, N-(2-hydroxy-5-nitrobenzoyl)-L-α-glutamyl-L-lysyl-L-homoseryl-, cyclic (1→3)-ether;3-((4S,7S,10S)-7-(4-aminobutyl)-4-((carboxymethyl)carbamoyl)-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2H-benzo[b][1,5,8,11]oxatriazacyclotetradecin-10-yl)propanoic acid;MIM-D3 | | CAS: | 263251-78-1 | | MF: | C24H32N6O11 | | MW: | 580.55 | | EINECS: | | | Product Categories: | | | Mol File: | 263251-78-1.mol |  |
| | Tavilermide Chemical Properties |
| Boiling point | 1122.4±65.0 °C(Predicted) | | density | 1.341±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 3.59±0.10(Predicted) | | color | White to off-white | | Water Solubility | Water : 5 mg/mL (8.61 mM; adjust pH to 3-4 with HCl) |
| | Tavilermide Usage And Synthesis |
| Biological Activity | Tavilermide is a selective TrkA partial agonist. | | in vitro | Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye. Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF. | | target | |
| | Tavilermide Preparation Products And Raw materials |
|